Shi Four Medicine Group (02005) recorded a year-on-year decrease of approximately 59.5% in net profit attributable to shareholders in the first quarter to approximately HK$168 million.

Wisdom Financial News APP, Shi Si Pharm (02005) announced its first quarter performance in 2025, with a year-on-year decrease in revenue of 36.9% to approximately HK$1.136 billion, mainly due to a decrease in sales volume of intravenous infusions and unaudited revenue of ampoule injections. Gross profit decreased by 50.6% to approximately HK$509 million, with a gross profit margin of approximately 44.8% (compared to approximately 57.3% in the same period in 2024). Share of profit attributable to shareholders decreased by approximately 59.5% to approximately HK$168 million.